Medicines planning
46 results
Applied filters
Biosimilar and key generic medicines – September 2026 update
16 September 2026An update around biosimilar and key generic medicines to support system planning and mobilisation.
Preparing to use ustekinumab biosimilar
31 July 2026Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
The licence and supporting evidence for ustekinumab biosimilars
31 July 2026Ustekinumab biosimilars are available for use within the NHS. Learn about indications, formulations, supporting evidence and differences.
Preparing to use golimumab biosimilar
21 July 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
The licence and supporting evidence for omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
Preparing to use omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.
Biosimilar insulin: a primary care discussion
1 July 2026A discussion about the considerations of implementing biosimilar insulin in primary care.
Biosimilar and key generic medicines – June 2026 update
25 June 2026An update about biosimilar and key generic medicines to support system planning and mobilisation
The licence and supporting evidence for golimumab biosimilar
2 June 2026We highlight evidence for available golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for denosumab 60mg biosimilars
24 April 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.